Literature DB >> 28419263

Renal Toxicity in Pediatric Patients Receiving Cidofovir for the Treatment of Adenovirus Infection.

Surabhi B Vora1, Adam W Brothers2, Janet A Englund1.   

Abstract

Treatment options for adenovirus infection in immunocompromised children are limited. Nephrotoxicity has been associated with cidofovir use, but the rate of cidofovir-associated nephrotoxicity in pediatric patients is unclear. In a retrospective review of patients with adenovirus infection treated with cidofovir, neonates (n = 5) had higher viral loads and shorter times to renal insufficiency than older children (n = 24). Higher weekly doses of cidofovir were associated with greater increases in creatinine levels. Of 29 courses of cidofovir, 9 were complicated by acute kidney injury; in these children, mortality was high. Cidofovir dosing in children needs to be optimized, and other therapeutic alternatives should be developed.
© The Author 2017. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  adenovirus; brincidofovir; cidofovir; nephrotoxicity; pediatrics

Mesh:

Substances:

Year:  2017        PMID: 28419263     DOI: 10.1093/jpids/pix011

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  10 in total

1.  Outcomes of human adenovirus infection and disease in a retrospective cohort of pediatric solid organ transplant recipients.

Authors:  Craig L K Boge; Brian T Fisher; Hans Petersen; Alix E Seif; Dale R Purdy; Despoina M Galetaki; Richard L Hodinka; Ana María Cárdenas; Adriana E Kajon
Journal:  Pediatr Transplant       Date:  2019-06-18

2.  Virus-specific T cells for adenovirus infection after stem cell transplantation are highly effective and class II HLA restricted.

Authors:  Jeremy D Rubinstein; Xiang Zhu; Thomas Leemhuis; Giang Pham; Lorraine Ray; Sana Emberesh; Sonata Jodele; Shawn Thomas; Jose A Cancelas; Catherine M Bollard; Patrick J Hanley; Michael D Keller; Olivia Grimley; Diana Clark; Teri Clark; Cecilia S Lindestam Arlehamn; Alessandro Sette; Stella M Davies; Adam S Nelson; Michael S Grimley; Carolyn Lutzko
Journal:  Blood Adv       Date:  2021-09-14

3.  Mapping Adverse Outcome Pathways for Kidney Injury as a Basis for the Development of Mechanism-Based Animal-Sparing Approaches to Assessment of Nephrotoxicity.

Authors:  Angela Mally; Sebastian Jarzina
Journal:  Front Toxicol       Date:  2022-06-15

4.  Filociclovir Is a Potent In Vitro and In Vivo Inhibitor of Human Adenoviruses.

Authors:  Karoly Toth; Islam T M Hussein; Ann E Tollefson; Baoling Ying; Jacqueline F Spencer; Jessica Eagar; Scott H James; Mark N Prichard; William S M Wold; Terry L Bowlin
Journal:  Antimicrob Agents Chemother       Date:  2020-10-20       Impact factor: 5.191

Review 5.  Successful Use of Cidofovir in an Immunocompetent Child With Severe Adenoviral Sepsis.

Authors:  Alicia M Alcamo; Michael S Wolf; Lauren J Alessi; Hey J Chong; Michael Green; John V Williams; Dennis W Simon
Journal:  Pediatrics       Date:  2019-12-11       Impact factor: 7.124

6.  Association between adenovirus viral load and mortality in pediatric allo-HCT recipients: the multinational AdVance study.

Authors:  Marco Zecca; Robert Wynn; Jean-Hugues Dalle; Tobias Feuchtinger; Enrikas Vainorius; Thomas M Brundage; Aastha Chandak; Essy Mozaffari; Garrett Nichols; Franco Locatelli
Journal:  Bone Marrow Transplant       Date:  2019-02-25       Impact factor: 5.483

7.  Therapeutic strategies to address monkeypox.

Authors:  Matthew W McCarthy
Journal:  Expert Rev Anti Infect Ther       Date:  2022-08-17       Impact factor: 5.854

8.  The use of intravesical cidofovir for the treatment of adenovirus-associated haemorrhagic cystitis in a kidney transplant recipient.

Authors:  Quan Yao Ho; Chieh Suai Tan; Siew Yee Thien; Terence Kee; Maciej Piotr Chlebicki
Journal:  Clin Kidney J       Date:  2019-02-18

Review 9.  Experience with Cidofovir as an adjunctive therapy in a patient of adenovirus-induced macrophage activation syndrome in systemic arthritis.

Authors:  Priyankar Pal; Niladri Bose; Avishek Poddar; Kaustabh Chowdhury; Agnisekhar Saha
Journal:  Clin Rheumatol       Date:  2020-05-17       Impact factor: 2.980

10.  Adenovirus Co-Opts Neutrophilic Inflammation to Enhance Transduction of Epithelial Cells.

Authors:  James M Readler; Meghan R Burke; Priyanka Sharma; Katherine J D A Excoffon; Abimbola O Kolawole
Journal:  Viruses       Date:  2021-12-22       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.